FY2026 EPS Estimates for Moderna, Inc. Raised by Brookline Capital Management (NASDAQ:MRNA)

Moderna, Inc. (NASDAQ:MRNA) – Investment analysts at Brookline Capital Management lifted their FY2026 earnings per share estimates for Moderna in a report released on Thursday, May 2nd. Brookline Capital Management analyst L. Cann now anticipates that the company will earn $12.97 per share for the year, up from their prior estimate of $12.50. The consensus estimate for Moderna’s current full-year earnings is ($7.47) per share. Brookline Capital Management also issued estimates for Moderna’s FY2027 earnings at $17.75 EPS and FY2028 earnings at $39.59 EPS.

Several other research analysts have also weighed in on MRNA. HSBC reissued a “reduce” rating and set a $86.00 price objective (up from $75.00) on shares of Moderna in a report on Monday, February 26th. Royal Bank of Canada boosted their price objective on Moderna from $125.00 to $135.00 and gave the company an “outperform” rating in a report on Friday. Jefferies Financial Group reaffirmed a “buy” rating and set a $125.00 target price on shares of Moderna in a report on Tuesday, April 9th. William Blair reiterated a “market perform” rating on shares of Moderna in a report on Monday, April 1st. Finally, Needham & Company LLC restated a “hold” rating on shares of Moderna in a research note on Thursday, May 2nd. Two investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and six have issued a buy rating to the company. According to data from MarketBeat, Moderna has a consensus rating of “Hold” and a consensus price target of $129.55.

Moderna Stock Down 2.3 %

Shares of NASDAQ:MRNA opened at $122.13 on Monday. Moderna has a 12-month low of $62.55 and a 12-month high of $142.79. The company has a current ratio of 4.03, a quick ratio of 3.91 and a debt-to-equity ratio of 0.04. The firm has a market cap of $46.81 billion, a PE ratio of -7.79 and a beta of 1.57. The company has a fifty day simple moving average of $105.61 and a 200 day simple moving average of $94.76.

Moderna (NASDAQ:MRNA) last announced its earnings results on Thursday, May 2nd. The company reported ($3.07) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($3.59) by $0.52. Moderna had a negative return on equity of 20.10% and a negative net margin of 115.82%. The company had revenue of $167.00 million for the quarter, compared to analyst estimates of $93.26 million. During the same period in the prior year, the company posted $0.19 EPS. Moderna’s quarterly revenue was down 91.0% on a year-over-year basis.

Insider Activity at Moderna

In other Moderna news, Director Noubar Afeyan sold 15,000 shares of the business’s stock in a transaction on Wednesday, May 1st. The stock was sold at an average price of $110.92, for a total transaction of $1,663,800.00. Following the completion of the transaction, the director now owns 2,026,931 shares in the company, valued at approximately $224,827,186.52. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Moderna news, Director Noubar Afeyan sold 15,000 shares of the business’s stock in a transaction dated Wednesday, May 1st. The shares were sold at an average price of $110.92, for a total transaction of $1,663,800.00. Following the sale, the director now directly owns 2,026,931 shares in the company, valued at approximately $224,827,186.52. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Shannon Thyme Klinger sold 670 shares of the company’s stock in a transaction that occurred on Thursday, February 29th. The stock was sold at an average price of $94.57, for a total transaction of $63,361.90. Following the completion of the sale, the insider now directly owns 8,557 shares of the company’s stock, valued at $809,235.49. The disclosure for this sale can be found here. Insiders have sold a total of 139,954 shares of company stock worth $14,822,576 in the last three months. 15.20% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Ogorek Anthony Joseph NY ADV bought a new stake in shares of Moderna in the 4th quarter worth approximately $27,000. Arlington Trust Co LLC grew its position in Moderna by 4,833.3% in the fourth quarter. Arlington Trust Co LLC now owns 296 shares of the company’s stock worth $29,000 after buying an additional 290 shares during the last quarter. Westside Investment Management Inc. bought a new position in shares of Moderna in the first quarter valued at $32,000. Rise Advisors LLC lifted its position in shares of Moderna by 953.3% during the 1st quarter. Rise Advisors LLC now owns 316 shares of the company’s stock valued at $34,000 after acquiring an additional 286 shares during the last quarter. Finally, UMB Bank n.a. boosted its stake in shares of Moderna by 121.8% during the 1st quarter. UMB Bank n.a. now owns 366 shares of the company’s stock worth $39,000 after acquiring an additional 201 shares in the last quarter. Institutional investors own 75.33% of the company’s stock.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.